BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Matos A, Viçosa A, Ré M, Ricci-júnior E, Holandino C. A review of current treatments strategies based on paromomycin for leishmaniasis. Journal of Drug Delivery Science and Technology 2020;57:101664. [DOI: 10.1016/j.jddst.2020.101664] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 dos Santos Matos AP, Lopes DCDXP, Peixoto MLH, da Silva Cardoso V, Vermelho AB, Santos-oliveira R, Viçosa AL, Holandino C, Ricci-júnior E. Development, characterization, and anti-leishmanial activity of topical amphotericin B nanoemulsions. Drug Deliv and Transl Res 2020;10:1552-70. [DOI: 10.1007/s13346-020-00821-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
2 Matha K, Calvignac B, Gangneux JP, Benoit JP. The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking. Expert Opin Drug Deliv 2021;18:471-87. [PMID: 33217254 DOI: 10.1080/17425247.2021.1853701] [Reference Citation Analysis]
3 Silva CFM, Pinto DCGA, Fernandes PA, Silva AMS. Evolution of Acridines and Xanthenes as a Core Structure for the Development of Antileishmanial Agents. Pharmaceuticals 2022;15:148. [DOI: 10.3390/ph15020148] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kumari D, Perveen S, Sharma R, Singh K. Advancement in leishmaniasis diagnosis and therapeutics: An update. Eur J Pharmacol 2021;910:174436. [PMID: 34428435 DOI: 10.1016/j.ejphar.2021.174436] [Reference Citation Analysis]